Bavarian Nordic (BVNRY) Stock Price, News & Analysis

Company Overview

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.

Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis. Its portfolio includes vaccines used in routine, travel and outbreak-response settings.

Founded in 1994 and headquartered in Hellerup, Denmark, Bavarian Nordic has developed specialized vaccine production capabilities and works with public-sector customers on preparedness for infectious disease threats. The company also conducts research and development aimed at expanding its vaccine portfolio and addressing additional unmet needs in infectious disease prevention.

Key Stats

• Today's Range: $10.51 to $10.54
• 50-Day Range: $8.76 to $11.44
• 52-Week Range: $8.67 to $13.00
• Volume: 3,210 shs
• Average Volume: 3,821 shs
• Market Capitalization: $2.50 billion
• P/E Ratio: 10.61
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/21/2026
• Today: 9/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BVNRY
• CIK: N/A
• Web: www.bavarian-nordic.com
• Phone: (453) 326-8383
• Fax: 45-3326-8380
• Employees: 1,692
• Year Founded: 1994

Profitability

• EPS (Trailing Twelve Months): $0.99
• Trailing P/E Ratio: 10.61
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $208.23 million
• Net Margins: 24.36%
• Pretax Margin: 26.40%
• Return on Equity: 12.06%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.47
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: $945.43 million
• Price / Sales: 2.64
• Cash Flow: $1.35 per share
• Price / Cash Flow: 7.80
• Book Value: $8.20 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 237,710,000
• Free Float: N/A
• Market Cap: $2.50 billion
• Optionable: Not Optionable
• Beta: 1.20